Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication Paolo Gresele, MD, PhD, Rino Migliacci, MD, PhD, Enrico Arosio, MD, Erminio Bonizzoni, PhD, Pietro Minuz, MD, Francesco Violi, MD Journal of Vascular Surgery Volume 56, Issue 6, Pages 1622-1628.e5 (December 2012) DOI: 10.1016/j.jvs.2012.05.064 Copyright © 2012 Society for Vascular Surgery Terms and Conditions
Fig 1 Flow chart of the trial profile. ITT, Intention to treat; OT, on-treatment. Journal of Vascular Surgery 2012 56, 1622-1628.e5DOI: (10.1016/j.jvs.2012.05.064) Copyright © 2012 Society for Vascular Surgery Terms and Conditions
Fig 2 Evolution of the absolute claudication distance (ACD) during the trial in patients treated with NCX 4016 or placebo. Data are shown as geometric means ± standard deviation and refer to the intima-media thickness (IMT) analysis. Journal of Vascular Surgery 2012 56, 1622-1628.e5DOI: (10.1016/j.jvs.2012.05.064) Copyright © 2012 Society for Vascular Surgery Terms and Conditions
Fig 3 Change from baseline in the mean intima-media thickness (IMT) of the right common carotid artery after 6 months of treatment with either NCX 4016 or placebo. Data represent means ± standard deviation. *P = .0306 vs baseline. Journal of Vascular Surgery 2012 56, 1622-1628.e5DOI: (10.1016/j.jvs.2012.05.064) Copyright © 2012 Society for Vascular Surgery Terms and Conditions